Pembrolizumab recommended for head and neck cancer
Treatment recommended as monotherapy for untreated metastatic or unresectable recurrent HNSCC, in NICE final draft guidance.
NICE guidance
Carfilzomib in combination not recommended for previously treated multiple myeloma
NICE says there is uncertainty about how long the benefit lasts after stopping
treatment in draft guidance.
Pembrolizumab with axitinib not recommended for untreated advanced renal cell carcinoma
NICE says cost-effectiveness estimates are uncertain.
Volanesorsen now recommended for familial chylomicronaemia syndrome
NICE's positive recommendation follows an improved discount to the treatment's price.